Skip to main content
. 2023 Apr 17;11(4):e006334. doi: 10.1136/jitc-2022-006334

Figure 4.

Figure 4

Validation of the Co-HA system. (A) Construction of the KRAS G12D TCR-T cells from healthy donors detected by FCM. (B) The specific proliferation levels of the KRAS G12D TCR-T cells detected by FCM after co-culture with the COS-7 cells expressing the relevant neoantigen in the Co-HA system. (C) The specific secretion of IFN-γ by TCR-T cells against the KRAS G12D neoantigen in the Co-HA system detected by ELISpot. (D) The specific secretion of IFN-γ by TCR-T cells against the KRAS G12D neoantigen in the Co-HA system detected by ELISA. (E) The specific lysis of the COS-7 cells generated by the KRAS G12D neoantigen in the Co-HA system detected by Sanger sequencing. (F) The LDH levels induced by TCR-T cells against the KRAS G12D neoantigen in the Co-HA system detected by ELISA. FCM, flow cytometry; ELISpot, enzyme-linked immunospot assay; IFN-γ, interferon-γ; LDH, lactate dehydrogenase; TCR, T-cell receptor.